

Supporting Information

Metal-Free Decarboxylative Annulation of *N*-Arylacrylamides with Vinyl Acids toward Benzo[*b*]azepin-2-ones

Gao-Ang Pan, Yang Li,* and Jin-Heng Li *

*Key Laboratory of Jiangxi Province for Persistent Pollutants Control and Resources
Recycle, Nanchang Hangkong University, Nanchang 330063, China, State Key
Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and
Chemical Engineering, Hunan University, Changsha 410082, China, and State Key
Laboratory of Applied Organic Chemistry Lanzhou University, Lanzhou 730000,
China*

liyang8825490@126.com and jhli@hnu.edu.cn

List of Contents


(A) Typical experimental procedure	S1-S2
(B) Analytical data	S2-S13
(C) Spectra	S14-S50
(D) The X-ray single-crystal diffraction analysis of 3ca	S51

(A) Typical Experimental Procedure

(a) General

The ^1H and ^{13}C NMR spectra were recorded in CDCl_3 solvent on a NMR spectrometer using TMS as internal standard. HRMS was measured on an electrospray ionization (ESI) apparatus using time-of-flight (TOF) mass spectrometry. Melting points are uncorrected.

(b) General procedure for synthesis of compound **3aa**.




To a Schlenk tube were added *N*-methyl-*N*-phenylmethacrylamide **1a** (0.2 mmol, 35 mg), 2,2-dimethylpent-4-enoic acid **2a** (2 equiv, 51.2 mg), $(\text{NH}_4)_2\text{S}_2\text{O}_8$ (2 equiv, 91.2 mg), and DMSO (2.0 mL). Then the mixture was stirred at 50 °C under argon atmosphere for indicated time until complete consumption of starting material as monitored by TLC and/or GC-MS analysis. After the reaction was finished, the reaction mixture was re-extracted with EtOAc. The organic phase was washed with brine. The combined organic extracts were dried over Na_2SO_4 and concentrated in vacuum. The residue was purified by silica gel flash column chromatography (hexane/ethyl acetate) to afford the compound **3aa** (36.0 mg, 0.14 mmol, 70% yield).

One millimol reaction: To a Schlenk tube were added *N*-methyl-*N*-phenylmethacrylamide **1a** (1.0mmol, 175 mg), 2,2-dimethylpent-4-enoic acid **2a** (2.0 equiv, 256 mg), $(\text{NH}_4)_2\text{S}_2\text{O}_8$ (2.0 equiv, 456 mg), and DMSO (5.0 mL). Then the mixture was stirred at 50 °C under argon atmosphere for indicated time until complete

consumption of starting material as monitored by TLC and/or GC-MS analysis. After the reaction was finished, the reaction mixture was re-extracted with EtOAc. The organic phase was washed with brine. The combined organic extracts were dried over Na₂SO₄ and concentrated in vacuum. The residue was purified by silica gel flash column chromatography (hexane/ethyl acetate) to afford the compound **3aa** (169.6 mg, 0.66 mmol, 66% yield).

(B) Analytical data


2,2,3a,5-Tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3aa), 36.0 mg, 70% yield; (dr = 1:1):



Yellow oil; ¹H NMR (500 MHz, CDCl₃): δ 0.86 (s, 3H), 0.99 (s, 3H), 1.09 (s, 3H), 1.19-1.16 (m, 1H), 1.40 (t, *J* = 12.0 Hz, 1H), 1.67-1.63 (m, 1H), 2.38-2.31 (m, 1H), 2.65-2.57 (m, 2H), 3.06 (d, *J* = 14.0 Hz, 1H), 3.42 (s, 3H), 7.12-7.09 (m, 2H), 7.18 (d, *J* = 7.5 Hz, 1H), 7.28-7.25 (m, 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 28.6, 28.8, 30.2, 36.6, 36.7, 38.41, 49.9, 52.3, 53.1, 56.3, 122.2, 125.4, 127.4, 128.3, 135.4, 144.1, 176.7; LRMS (EI, 70 eV) *m/z* (%): 257 (M⁺, 30), 229 (73), 144 (35), 120 (100); HRMS *m/z* (ESI) calcd for C₁₇H₂₄NO ([M+H]⁺) 258.1852, found 258.1858.

Yellow oil; ¹H NMR (500 MHz, CDCl₃): δ 0.89 (s, 3H), 1.04 (s, 3H), 1.09 (s, 3H), 1.48-1.41 (m, 2H), 1.75-1.72 (m, 1H), 2.78-2.68 (m, 3H), 3.35 (s, 3H), 3.42-3.37 (m, 1H), 7.03 (t, *J* = 7.0 Hz, 1H), 7.10-7.09 (m, 2H), 7.17 (t, *J* = 7.5 Hz, 1H); ¹³C{¹H} NMR (125 MHz, CDCl₃): δ 18.1, 31.3, 31.6, 35.2, 35.5, 39.0, 43.3, 48.9, 52.1, 53.0, 122.8, 124.3, 126.3, 130.8, 132.6, 143.2, 178.4.


5-Cyclohexyl-2,2,3a-trimethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ba), 26.0 mg, 40% yield; (dr = 1:1):



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.76 (s, 3H), 0.97 (s, 3H), 1.09 (s, 3H), 1.14-1.10 (m, 2H), 1.46-1.34 (m, 4H), 1.55-1.49 (m, 1H), 1.61-1.58 (m, 1H), 1.74-1.71 (m, 1H), 1.87-1.84 (m, 2H), 2.07 (d, $J = 12.0$ Hz, 1H), 2.27-2.19 (m, 1H), 2.63-2.56 (m, 2H), 3.09 (d, $J = 14.0$ Hz, 1H), 4.42-4.36 (m, 1H), 7.18-7.13 (m, 3H), 7.25-7.22 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 25.7, 26.4, 26.4, 28.2, 29.0, 30.2, 30.8, 32.8, 36.4, 36.7, 49.8, 52.3, 53.0, 56.2, 60.3, 124.9, 126.1, 126.8, 128.0, 137.4, 141.7, 175.8; LRMS (EI, 70 eV) m/z (%): 325 (M^+ , 11), 243 (100), 228 (24), 144 (36); HRMS m/z (ESI) calcd for $\text{C}_{22}\text{H}_{32}\text{NO}$ ($[\text{M}+\text{H}]^+$) 326.2478, found 326.2485.

Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.63 (s, 3H), 1.05 (d, $J = 5.0$ Hz, 6H), 1.18-1.12 (m, 1H), 1.38-1.28 (m, 4H), 1.53 (t, $J = 13.0$ Hz, 1H), 1.62-1.58 (m, 2H), 1.82-1.75 (m, 3H), 1.96-1.88 (m, 1H), 2.14 (d, $J = 10.0$ Hz, 1H), 2.51-2.46 (m, 2H), 2.73-2.66 (m, 1H), 3.33-3.28 (m, 1H), 4.07-4.01 (m, 1H), 7.11-7.08 (m, 2H), 7.21-7.18 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.2, 25.7, 26.4, 26.5, 31.4, 31.4, 32.3, 32.4, 33.4, 34.8, 46.6, 47.3, 52.3, 52.4, 62.2, 125.8, 126.1, 126.5, 130.5, 136.2, 142.5, 176.8.

5-Benzyl-2,2,3a-trimethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ca), 34.0 mg, 51% yield; (dr = 1:1):




White solid; mp 114.1-117.1 $^{\circ}\text{C}$ (uncorrected); ^1H NMR (500 MHz, CDCl_3): δ 0.99 (d, $J = 9.5$ Hz, 6H), 1.08 (s, 3H), 1.20-1.17 (m, 1H), 1.39 (t, $J = 12.0$ Hz, 1H), 1.64-1.61 (m, 1H), 2.40-2.33 (m, 1H), 2.58-2.48 (m, 2H), 3.09 (d, $J = 14.0$ Hz, 1H), 4.91 (d, $J = 15.0$ Hz, 1H), 5.22 (d, $J = 15.0$ Hz, 1H), 7.15-7.08 (m, 3H), 7.26-7.18 (m, 5H), 7.28 (d, $J = 8.0$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 28.5, 28.8, 30.1, 36.7, 36.8, 49.9, 52.3, 53.1, 54.6, 56.4, 122.1, 125.6, 126.9, 127.1, 127.5, 128.4, 135.7, 138.7, 143.5, 176.7; LRMS (EI, 70 eV) m/z (%): 333 (M^+ , 23), 237 (42), 207 (3), 91 (100); HRMS m/z (ESI) calcd for $\text{C}_{23}\text{H}_{28}\text{NO}$ ($[\text{M}+\text{H}]^+$) 334.2165, found 334.2170.

White solid; mp 99.3-103.0 $^{\circ}\text{C}$ (uncorrected); ^1H NMR (500 MHz, CDCl_3): δ 0.94 (s, 3H), 1.01 (s, 3H), 1.08 (s, 3H), 1.39 (d, $J = 14$ Hz, 1H), 1.49 (t, $J = 12.5$ Hz, 1H),


1.72-1.69 (m, 1H), 2.74-2.65 (m, 3H), 3.34-3.29 (m, 1H), 5.04 (d, $J = 15.5$ Hz, 1H), 5.11 (d, $J = 15.5$ Hz, 1H), 7.00 (t, $J = 7.0$ Hz, 1H), 7.13-7.06 (m, 3H), 7.21-7.18 (m, 3H), 7.29-7.26 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.2, 31.2, 31.4, 34.8, 35.5, 44.0, 48.5, 52.0, 52.7, 54.6, 123.6, 124.8, 126.5, 126.7, 126.8, 128.3, 130.9, 133.5, 138.6, 142.6, 177.3.

2,2,3a-Trimethyl-5-phenyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3da), 40.2 mg, 63% yield; (dr = 1.2:1):



Yellow oil; ^1H NMR (500 MHz, CDCl_3): δ 1.02 (d, $J = 7.0$ Hz, 3H), 1.07 (s, 4H), 1.10 (s, 2H), 1.24-1.21 (m, 0.45H), 1.54-1.39 (m, 2H), 1.70-1.67 (m, 0.45H), 1.80-1.76 (m, 0.55H), 2.51-2.44 (m, 0.55H), 2.80-2.76 (m, 1H), 2.88-2.84 (m, 1H), 3.08 (d, $J = 14.0$ Hz, 0.45H), 3.55-3.48 (m, 0.55H), 6.68-6.66 (m, 0.55H), 6.74-6.72 (m, 0.45H), 7.00-6.92 (m, 1H), 7.10-7.08 (m, 0.9H), 7.15-7.13 (m, 1.1H), 7.27-7.22 (m, 3H), 7.40-7.34 (m, 2H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.2, 28.2, 29.0, 30.1, 30.8, 31.4, 31.4, 35.9, 36.7, 36.8, 43.2, 48.7, 49.9, 52.1, 52.2, 52.5, 53.6, 56.5, 124.3, 124.7, 125.4, 126.1, 126.5, 126.5, 126.8, 127.4, 128.1, 128.4, 128.9, 129.0, 129.0, 131.0, 132.6, 135.4, 142.5, 143.4, 144.5, 144.6, 177.0, 177.1; LRMS (EI, 70 eV) m/z (%): 319 (M^+ , 73), 206 (90), 180 (100), 143 (60); HRMS m/z (ESI) calcd for $\text{C}_{22}\text{H}_{26}\text{NO}$ ($[\text{M}+\text{H}]^+$) 320.2009, found 320.2016.


2,2,3a-Trimethyl-5-tosyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ea), 47.6 mg, 60% yield; (dr = 2:1):



White solid; mp 183.8-185.3 °C (uncorrected); ^1H NMR (500 MHz, CDCl_3): δ 0.76 (s, 5H), 0.93 (d, $J = 16.5$ Hz, 2H), 1.02 (s, 2H), 1.08-1.05 (m, 0.7H), 1.43-1.34 (m, 1H), 1.54-1.50 (m, 0.3H), 1.68-1.65 (m, 1H), 2.21-2.15 (m, 0.3H), 2.27 (d, $J = 14.0$ Hz, 0.7H), 2.35 (t, $J = 13.0$ Hz, 0.3H), 2.44 (s, 3H), 2.67-2.55 (m, 1H), 2.82-2.72 (m, 1H), 3.52-3.47 (m, 0.7H), 7.25-7.18 (m, 3H), 7.36-7.30 (m, 2.7H), 7.51 (d, $J = 7.5$ Hz, 0.3H), 7.87 (d, $J = 8.0$ Hz, 0.6H), 8.02 (d, $J = 8.0$ Hz, 1.4H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.8, 21.6, 21.6, 27.0, 28.9, 29.7, 30.4, 31.2, 34.0, 35.6, 36.9, 41.5, 47.6, 49.2, 51.4,

52.7, 53.8, 54.1, 55.3, 126.3, 127.0, 128.3, 128.3, 128.8, 128.9, 129.0, 129.2, 129.2, 129.2, 129.5, 131.0, 134.8, 135.9, 136.4, 137.0, 144.4, 144.5, 175.9, 178.4; LRMS (EI, 70 eV) m/z (%): 397 (M^+ , 23), 243 (56), 206 (17), 106 (100); HRMS m/z (ESI) calcd for $C_{23}H_{28}NO_3S$ ($[M+H]^+$) 398.1784, found 398.1789.


2,2,3a,5,8-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ga), 39.0 mg, 72% yield; (dr = 2:1):



Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.87 (s, 3H); 0.99 (s, 3H), 1.08 (s, 3H), 1.17 (d, $J = 14.0$ Hz, 1H), 1.40 (t, $J = 12.5$ Hz, 1H), 1.66–1.60 (m, 2H), 2.33 (s, 3H), 2.56 (d, $J = 9.0$ Hz, 2H), 3.06 (d, $J = 14.0$ Hz, 1H), 3.38 (s, 3H), 6.99 (d, $J = 10.5$ Hz, 2H), 7.06 (d, $J = 8.0$ Hz, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 20.8, 28.6, 28.9, 30.2, 36.6, 36.7, 38.4, 50.0, 52.3, 53.1, 56.3, 77.3, 122.1, 128.0, 128.9, 135.1, 176.7; LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 73), 256 (56), 156 (68), 134 (100); LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 73), 256 (56), 156 (68), 134 (100); HRMS m/z (ESI) calcd for $C_{18}H_{26}NO$ ($[M+H]^+$) 272.2009, found 272.2014.

1H NMR (500 MHz, $CDCl_3$): δ 0.89 (s, 3H), 1.04 (s, 3H), 1.09 (s, 3H), 1.47–1.40 (m, 2H), 1.74–1.70 (m, 1H), 2.28 (s, 3H), 2.75–2.64 (m, 3H), 3.39–3.31 (m, 4H), 6.90 (s, 1H), 7.00–6.95 (m, 2H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 18.1, 20.4, 31.2, 31.6, 35.1, 35.6, 38.9, 43.3, 48.9, 52.1, 53.0, 122.7, 127.0, 131.2, 132.2, 132.2, 133.8, 140.8, 178.4.

8-Methoxy-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ha), 18.9 mg, 33% yield; (dr = 1:1):




Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.88 (s, 3H), 0.99 (s, 3H), 1.08 (s, 3H), 1.19–1.16 (m, 1H), 1.39 (t, $J = 12.0$, 1H), 1.65–1.61 (m, 1H), 2.37–2.30 (m, 1H), 2.57 (d, 2H), 3.06 (d, $J = 13.5$ Hz, 1H), 3.82 (s, 3H), 3.37 (s, 3H), 6.71 (d, $J = 3.0$ Hz, 1H), 6.81–6.78 (m, 1H), 7.03 (d, $J = 9.0$ Hz, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 28.6, 28.8, 30.2, 36.7, 36.8, 38.5, 49.9, 52.2, 52.9, 55.4, 56.0, 112.5, 113.3, 123.4, 136.7, 137.1, 156.9,

176.6 ; LRMS (EI, 70 eV) m/z (%): 287 (M^+ , 100), 272 (42), 174 (35), 150 (54); HRMS m/z (ESI) calcd for $C_{18}H_{25}NO_2$ ($[M+H]^+$) 288.1958, found 288.1952.


Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.89 (s, 3H), 1.04 (s, 3H), 1.09 (s, 3H), 1.48-1.40 (m, 2H), 1.73-1.70(m, 1H), 2.76-2.64 (m, 3H), 3.32 (s, 3H), 3.38-3.34 (m, 1H), 3.79 (s, 3H), 6.61 (d, J = 2.5 Hz, 1H), 6.73-6.71 (m, 1H), 7.01 (d, J = 9.0 Hz, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 18.1, 31.3, 31.6, 35.3, 35.5, 39.0, 43.42, 48.9, 52.0, 53.0, 55.3, 112.0, 115.0, 124.0, 134.0, 136.7, 155.8, 178.3.

8-Fluoro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ia), 33.0 mg, 60% yield; (dr = 2:1):



Yellow oil; 1H NMR (500MHz, $CDCl_3$): δ 0.87 (s, 2H), 0.89 (s, 1H), 1.00 (s, 2H), 1.04 (s, 1H), 1.09 (d, J = 3.5 Hz, 3H), 1.20-1.17 (m, 0.67H), 1.38 (d, J = 12.0, 0.33H), 1.48-1.41 (m, 1H), 1.66-1.63 (m, 0.67H), 1.75-1.71 (m, 0.33H), 2.38-2.31(m, 0.67H), 2.60-2.58 (t, J = 5.0Hz, 1H), 2.72-2.65 (m, 1H), 2.77-2.73 (m, 0.33H), 3.06 (d, J = 14.0 Hz, 0.67H), 3.32 (s, 1H), 3.37-3.34 (m, 0.33H), 3.39(s, 2H), 6.82-6.80 (m, 0.33H), 6.90-6.85 (m, 1H), 6.98-6.94 (m, 0.67H), 7.09-7.04 (m, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 18.1, 28.5, 28.8, 30.1, 31.2, 31.5, 35.1, 35.5, 36.6, 36.7, 38.5, 39.1, 43.2, 48.8, 49.8, 52.0, 52.2, 52.9, 52.9, 55.9, 113.3 (d, J_{C-F} = 22.0 Hz), 114.0 (d, J_{C-F} = 22.4 Hz), 114.8 (d, J_{C-F} = 22.0 Hz), 116.6 (d, J_{C-F} = 21.6 Hz), 123.7 (d, J_{C-F} = 8.5 Hz), 124.4 (d, J_{C-F} = 8.3 Hz), 134.9(d, J_{C-F} = 7.0 Hz), 137.5(d, J_{C-F} = 7.6 Hz), 139.4 (d, J_{C-F} = 2.9 Hz), 140.1(d, J_{C-F} = 2.9 Hz), 158.9 (d, J_{C-F} = 243.4 Hz), 159.7 (d, J_{C-F} = 243.9 Hz), 176.4, 178.2; ^{19}F NMR (471 MHz, $CDCl_3$): δ -119.3, -116.9; LRMS (EI, 70 eV) m/z (%): 275 (M^+ , 56), 260 (55), 162 (55), 138 (100); HRMS m/z (ESI) calcd for $C_{17}H_{23}FNO$ ($[M+H]^+$) 276.1758, found 276.1763.


8-Chloro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ja), 37.8 mg, 65% yield; (dr = 1.3:1):




Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.89 (s, 1.7H), 0.91 (s, 1.3H), 1.00 (s, 1.7H), 1.03 (s, 1.3H), 1.09 (d, J = 4.5 Hz, 3H), 1.20-1.17(m, 1H), 1.44-1.37 (m, 1H), 1.67-1.63 (m,

0.57H), 1.75-1.73 (m, 0.43H), 2.38-2.31 (m, 0.57H), 2.60-2.56 (m, 1H), 2.73-2.68 (m, 1H), 2.77-2.74 (m, 0.43H), 3.05 (d, $J = 13.5$ Hz, 0.57H), 3.32 (s, 1.3H), 3.36-3.33(m, 0.43H), 3.38 (s, 1.7H), 7.06-7.02 (m, 1H), 7.06-7.02 (m, 1H), 7.14-7.11 (m, 0.43H), 7.17 (d, $J = 2.5$ Hz, 0.57H), 7.25-7.22 (m, 0.57H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.2, 28.6, 28.7, 30.1, 31.1, 31.5, 35.0, 35.6, 36.4, 36.7, 38.4, 39.0, 42.9, 48.8, 49.8, 52.0, 52.2, 52.9, 53.1, 55.9, 123.4, 124.1, 126.4, 127.4, 128.2, 129.3, 130.3, 130.3, 134.4, 137.1, 141.8, 142.6, 176.5, 178.2; LRMS (EI, 70 eV) m/z (%): 291 ($\text{M}^+ + 2$, 73), 276 (51), 178 (70), 154 (100); HRMS m/z (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{ClNO}$ ($[\text{M} + \text{H}]^+$) 292.1463, found 292.1468.

8-Bromo-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ka), 42.2 mg, 63% yield; (dr = 1.5:1):


 Yellow oil; ^1H NMR (500 MHz, CDCl_3): δ 0.89 (s, 1.2H), 0.91 (s, 1.8H), 1.00 (s, 1.2H), 1.03 (s, 1.8H), 1.09 (d, $J = 5.0$ Hz, 3H), 1.20-1.17(m, 0.6H), 1.37 (d, $J = 12.5$ Hz, 0.4H), 1.43 (d, $J = 14.0$ Hz, 1H), 1.67-1.63 (m, 0.4H), 1.75-1.72 (m, 0.6H), 2.38-2.31(m, 0.4H), 2.58 – 2.56 (m, 0.6H), 2.75-2.66 (m, 2H), 3.04 (d, $J = 14.0$ Hz, 0.4H), 3.32 (s, 1.8H), 3.37-3.33 (m, 0.6H), 3.38 (s, 1.2H), 7.00-6.95 (m, 1H), 7.28-7.25 (m, 1.2H), 7.32 (d, $J = 2.0$ Hz, 0.4H), 7.39-7.37 (m, 0.4H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125MHz, CDCl_3): δ 18.3, 28.7, 28.8, 30.2, 31.2, 31.6, 35.1, 35.7, 36.5, 36.8, 38.4, 39.1, 43.0, 48.85, 49.9, 52.1, 52.3, 53.0, 53.2, 56.0, 76.8, 77.1, 77.3, 117.2, 123.8, 124.5, 129.4, 130.5, 131.2, 133.3, 134.8, 137.5, 142.4, 143.3, 176.5, 178.3; LRMS (EI, 70 eV) m/z (%): 335 ($\text{M}^+ + 2$, 65), 222 (100), 198 (97), 117 (74); HRMS m/z (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{BrNO}$ ($[\text{M} + \text{H}]^+$) 336.0958, found 336.0951.

2,2,3a,5-Tetramethyl-8-(trifluoromethyl)-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3la), 33.8mg, 52% yield; (dr = 1.1:1):

 Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.88 (s, 1.4H), 0.92 (s, 1.6H), 1.01 (s, 1.4H), 1.05 (s, 1.6H), 1.10 (d, $J = 5.5$ Hz, 3H), 1.20-1.19 (m, 0.53H), 1.31 (d, $J = 25.5$ Hz, 0.47H), 1.49-1.42 (m, 1H), 1.70-1.66 (m, 0.47H), 1.79-1.75 (m, 0.53H), 2.41-2.36 (m, 0.47H),


2.81-2.64 (m, 2.53H), 3.06 (d, $J = 14.0$ Hz, 0.47H), 3.37 (s, 1.4H), 3.41-3.38(m, 0.53H), 3.43 (s, 1.6H), 7.23-7.19 (m, 1H), 7.45-7.37 (m, 1.53H), 7.53 (d, $J = 8.5$ Hz, 0.47H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 18.3, 28.7, 28.7, 30.1, 31.1, 31.5, 35.3, 35.7, 36.7, 36.7, 38.4, 39.1, 42.7, 48.8, 49.9, 52.2, 52.3, 53.0, 53.4, 55.9, 122.2, 123.1, 123.3(q, $J_{\text{C-F}} = 3.6$ Hz), 124.5 (q, $J_{\text{C-F}} = 3.8$ Hz), 123.9 (q, $J_{\text{C-F}} = 274.0$ Hz), 123.9 (q, $J_{\text{C-F}} = 266.5$ Hz), 125.4 (q, $J_{\text{C-F}} = 3.6$ Hz), 126.1 (d, $J_{\text{C-F}} = 32.5$ Hz), 127.1 (d, $J_{\text{C-F}} = 32.4$ Hz), 127.9 (q, $J_{\text{C-F}} = 3.6$ Hz), 133.0, 135.9, 146.0 (d, $J_{\text{C-F}} = 0.8$ Hz), 147.2 (d, $J_{\text{C-F}} = 1.1$ Hz), 176.6, 178.3; ^{19}F NMR (471 MHz, CDCl_3): δ -62.3, -62.2; LRMS (EI, 70 eV) m/z (%): 325 (M^+ , 51), 310 (52), 210 (42), 188 (100); HRMS m/z (ESI) calcd for $\text{C}_{18}\text{H}_{23}\text{F}_3\text{NO}$ ($[\text{M}+\text{H}]^+$) 326.1726, found 326.1721.

6-Chloro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ma), 23.9 mg, 41% yield:



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.85 (s, 3H), 0.99 (s, 3H), 1.10 (s, 3H), 1.18-1.15 (m, 1H), 1.38 (t, $J = 12.5$ Hz, 1H), 1.64-1.60 (m, 1H), 2.31-2.24 (m, 1H), 2.54 (t, $J = 13.0$ Hz, 1H), 2.66-2.62(m, 1H), 3.10 (d, $J = 14.0$ Hz, 1H), 3.28 (s, 3H), 7.14-7.10 (m, 2H), 7.33-7.31 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 27.5, 28.7, 30.0, 36.7, 37.0, 38.1, 49.6, 51.8, 52.3, 56.5, 126.5, 127.4, 129.0, 129.2, 138.9, 141.4, 177.0; LRMS (EI, 70 eV) m/z (%): 291 ($\text{M}^+ + 2$, 29), 276 (100), 154 (31), 117 (15); HRMS m/z (ESI) calcd for $\text{C}_{17}\text{H}_{23}\text{ClNO}$ ($[\text{M}+\text{H}]^+$) 292.1463, found 292.1472.


2,2,3a,5,7-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3na), 26.6 mg, 49% yield; (dr = 1.5:1):



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.82 (s, 1.2H), 0.87 (s, 1.8H), 0.99 (d, $J = 4.1$ Hz, 3H), 1.09 (d, $J = 4.0$ Hz, 3H), 1.18-1.15 (m, 1H), 1.42-1.39 (m, 1H), 1.67-1.61(m, 1H), 2.25-2.21 (m, 0.4H), 2.35 (d, $J = 4.5$ Hz, 3.6H), 2.61-2.51 (m, 1.6H), 2.87-2.84 (m, 0.4H), 3.09-3.04 (m, 1H), 3.40 (d, $J = 1.5$ Hz, 3H), 6.92 (d, $J = 8.0$ Hz, 1.2H), 7.06-6.96 (m, 0.8H), 7.05 (d, $J = 7.5$ Hz, 0.6H), 7.14 (t, $J = 8.0$ Hz, 0.4H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 19.9, 21.1, 28.4, 28.7, 28.8, 29.0, 30.2, 30.3, 31.6, 36.2, 36.7, 36.7, 38.4,


38.4, 49.9, 50.0, 52.3, 53.2, 53.2, 54.8, 56.3, 120.2, 122.8, 126.1, 126.6, 127.2, 128.0, 132.3, 133.8, 135.2, 137.2, 143.9, 144.3, 176.5, 176.8; LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 69), 256 (56), 156 (99), 134 (100); HRMS m/z (ESI) calcd for $C_{18}H_{26}NO$ ($[M+H]^+$) 272.2009, found 272.2014.

2,2,3a,5,9-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3na'), 13.0mg, 24% yield:




Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.90 (s, 3H), 1.04 (s, 3H), 1.10 (s, 3H), 1.31 (d, $J = 24.0$ Hz, 1H), 1.46-1.41 (m, 1H), 1.79-1.75 (m, 1H), 2.26 (s, 3H), 2.61-2.56 (m, 1H), 2.82-2.75 (m, 2H), 3.09-3.04 (m, 1H), 3.33 (s, 3H), 6.99-6.94 (m, 2H), 7.08 (t, $J = 8.0$ Hz, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 18.1, 21.0, 30.9, 31.5, 33.0, 36.0, 39.9, 43.0, 49.4, 51.8, 52.9, 121.3, 125.9, 126.3, 131.2, 137.5, 143.7, 178.9; LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 36), 243 (69), 158 (55), 134 (100); HRMS m/z (ESI) calcd for $C_{18}H_{26}NO$ ($[M+H]^+$) 272.2009, found 272.2014.

2,2,5-Trimethyl-3a-phenyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3oa), 29.3mg, 46% yield:



Yellow oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.92 (s, 3H), 1.19 (s, 3H), 1.31-1.28 (m, 1H), 1.65 (d, $J = 12.0$ Hz, 1H), 1.82-1.78 (m, 1H), 2.69 (t, $J = 13.0$ Hz, 1H), 2.83-2.79 (m, 1H), 3.25 (d, $J = 14.0$ Hz, 1H), 3.33 (s, 3H), 3.52-3.46 (m, 1H), 6.31 (d, $J = 7.5$ Hz, 1H), 6.31 (d, $J = 7.5$ Hz, 1H), 6.79-6.76 (m, 1H), 6.92-6.85 (m, 4H), 7.11-7.09 (m, 1H); $^{13}C\{^1H\}$ NMR (125 MHz, $CDCl_3$): δ 30.0, 31.0, 35.8, 36.6, 37.4, 48.5, 49.3, 54.6, 62.0, 123.0, 124.6, 125.1, 127.2, 127.4, 127.7, 136.3, 143.4, 145.5, 175.5; LRMS (EI, 70 eV) m/z (%): 319 (M^+ , 100), 263 (20), 205 (63), 120 (78); HRMS m/z (ESI) calcd for $C_{22}H_{26}NO$ ($[M+H]^+$) 320.2009, found 320.2016.


5,6a,8,8-Tetramethyl-1,2,3,5,6a,7,8,9,9a,10-decahydro-6*H*-cyclopenta[*e*]indeno[5,6-*b*]azepin-6-one (3pa), 27.9mg, 47% yield; (dr = 1:1):



Colorless oil; 1H NMR (500 MHz, $CDCl_3$): δ 0.86 (s, 1.5H), 0.88 (s, 1.5H), 0.99 (s, 1.5H), 1.00 (s, 1.5H), 1.08 (s, 1.5H),

1.09 (s, 1.5H), 1.17 (d, $J = 13.5$ Hz, 1H), 1.29 (s, 0.5 H), 1.43-1.36 (m, 1H), 1.65-1.62 (m, 0.5H), 2.13-2.08 (m, 2H), 2.32-2.25 (m, 1H), 2.46-2.41 (t, $J = 13.0$ Hz, 0.5 H), 2.57-2.53 (m, 1H), 2.72-2.68 (m, 0.5H), 2.94-2.87 (m, 4H), 3.09-3.05 (m, 1H), 3.39 (s, 3H), 6.91 (d, $J = 8.0$ Hz, 0.5H), 6.97 (s, 0.5H), 7.01 (s, 0.5H), 7.10 (d, $J = 7.5$ Hz, 0.5H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 25.1, 25.6, 28.6, 28.7, 28.9, 28.9, 30.2, 31.4, 32.4, 32.7, 32.9, 32.9, 36.6, 36.8, 36.8, 38.6, 350.0, 8.6, 49.9, 49.9, 52.2, 52.3, 53.0, 53.2, 55.2, 56.4, 118.2, 120.5, 122.6, 123.8, 131.0, 133.1, 141.3, 141.5, 141.9, 142.2, 142.2, 143.5, 176.7, 176.8; LRMS (EI, 70 eV) m/z (%): 297 (M^+ , 100), 282 (70), 182 (91), 160 (87); HRMS m/z (ESI) calcd for $\text{C}_{20}\text{H}_{28}\text{NO}$ ($[\text{M}+\text{H}]^+$) 298.2165, found 298.2160.


2,2-Diethyl-3a,5-dimethyl-2,3,3a,5,10,10a-hexahydrobenzo[*b*]cyclopenta[*e*]azepin-4(1*H*)-one (3ab), 29.6mg, 52% yield; (dr = 1:1):



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.77 (t, $J = 7.5$ Hz, 3H), 0.82 (t, $J = 7.5$ Hz, 6H), 0.87-0.85 (m, 1H), 1.23-1.19 (m, 1H), 1.36-1.31 (m, 2H), 1.43-1.39 (m, 2H), 1.80-1.76 (m, 1H), 2.31-2.24 (m, 1H), 2.66-2.55 (m, 2H), 2.97 (d, $J = 14.0$ Hz, 1H), 3.41 (s, 3H), 7.12-7.08 (m, 2H), 7.17 (d, $J = 7.0$ Hz, 1H), 7.28-7.26 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 8.6, 9.2, 28.4, 28.7, 31.2, 36.8, 38.3, 42.9, 46.2, 49.0, 52.6, 55.4, 122.1, 125.3, 127.4, 128.3, 135.3, 144.2, 176.7; LRMS (EI, 70 eV) m/z (%): 285 (M^+ , 50), 256 (100), 120 (96), 91 (25); HRMS m/z (ESI) calcd for $\text{C}_{19}\text{H}_{28}\text{NO}$ ($[\text{M}+\text{H}]^+$) 286.2165, found 286.2172.

Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.81 (t, $J = 7.0$ Hz, 6H), 0.89 (s, 3H), 1.42-1.33 (m, 6H), 1.84-1.80 (m, 1H), 2.73-2.63 (m, 3H), 3.34 (s, 3H), 3.41-3.36 (m, 1H), 7.04-7.01 (m, 1H), 7.09 (d, $J = 8.0$ Hz, 2H), 7.16 (t, $J = 7.5$ Hz, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 8.7, 9.2, 18.1, 30.9, 32.6, 35.4, 39.0, 41.9, 42.7, 45.4, 49.8, 51.4, 122.7, 124.2, 126.3, 130.8, 130.8, 143.1, 178.6.


3a,5-Dimethyl-1,3,3a,5,10,10a-hexahydro-4*H*-spiro[benzo[*b*]cyclopenta[*e*]azepine-2,1'-cyclobutan]-4-one (3ac), 37.7mg, 70% yield; (dr = 1.5:1):



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.81 (s, 3H), 1.50-1.46 (m, 1H), 1.69-1.56 (m, 1H), 1.88-1.77 (m, 5H), 2.03-1.97


(m, 2H), 2.15-2.11 (m, 0.6H), 2.56-2.52 (m, 0.4H), 2.61 (d, $J = 8.5$ Hz, 1H), 2.81-2.70 (m, 1H), 2.96 (s, 0.4H), 3.34 (s, 1.2H), 3.37 (t, $J = 9.0$ Hz, 0.6H), 3.40 (s, 1.8H), 7.04-7.01 (m, 0.4H), 7.12-7.08 (m, 2H), 7.17-7.15 (m, 1H), 7.27-7.24 (m, 0.6H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 16.6, 16.7, 17.0, 28.4, 31.2, 35.0, 35.3, 35.7, 36.4, 36.9, 38.4, 38.8, 43.4, 43.6, 44.4, 47.3, 47.8, 51.1, 51.4, 52.1, 52.8, 55.9, 122.2, 122.9, 124.3, 124.3, 126.4, 127.4, 128.3, 130.8, 132.7, 135.5, 135.5, 143.7, 176.7, 178.2; LRMS (EI, 70 eV) m/z (%): 269 (M^+ , 54), 241 (54), 226 (71), 120 (100); HRMS m/z (ESI) calcd for $\text{C}_{18}\text{H}_{24}\text{NO}$ ($[\text{M}+\text{H}]^+$) 270.1852, found 270.1847.

3a,5-Dimethyl-1,3,3a,5,10,10a-hexahydro-4*H*-spiro[benzo[*b*]cyclopenta[*e*]azepine-2,1'-cyclopentan]-4-one (3ad), 45.3mg, 80% yield; (dr = 1:1):



Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.86 (d, $J = 12.0$ Hz, 3H), 1.28 (d, $J = 14.0$ Hz, 0.5H), 1.46-1.39 (m, 1.5H), 1.62-1.49 (m, 8H), 1.75-1.71 (m, 0.5H), 1.83-1.79 (m, 0.5H), 2.23-2.16 (m, 0.5H), 2.7-2.60 (m, 2.5H), 3.13 (d, $J = 13.5$ Hz, 0.5H), 3.35 (s, 1.5H), 3.38 (d, $J = 8.5$ Hz, 0.5H), 3.42 (s, 1.5H), 7.03 (t, $J = 7.0$ Hz, 0.5H), 7.13-7.09 (m, 2H), 7.18-7.15 (m, 1H), 7.28-7.25 (m, 0.5H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 17.7, 23.8, 24.0, 24.2, 24.8, 28.3, 35.1, 36.6, 38.4, 38.5, 38.8, 39.3, 41.3, 41.4, 44.2, 46.8, 46.9, 47.5, 48.0, 50.5, 51.3, 51.4, 52.3, 56.7, 122.2, 122.2, 124.3, 125.3, 126.3, 127.3, 128.2, 130.7, 132.7, 135.4, 143.2, 143.8, 176.8, 178.3; LRMS (EI, 70 eV) m/z (%): 283 (M^+ , 58), 224 (26), 142 (38), 120 (100); HRMS m/z (ESI) calcd for $\text{C}_{19}\text{H}_{26}\text{NO}$ ($[\text{M}+\text{H}]^+$) 284.2009, found 284.2014.


3a,5-Dimethyl-1,3,3a,5,10,10a-hexahydro-4*H*-spiro[benzo[*b*]cyclopenta[*e*]azepine-2,1'-cycloheptan]-4-one (3ae), 37.9mg, 61% yield; (dr = 2:1):



Yellow oil; ^1H NMR (500 MHz, CDCl_3): δ 0.83 (s, 1.1H), 0.88 (s, 1.9H), 1.36-1.27 (m, 2H), 1.55-1.42 (m, 10H), 1.66-1.59 (m, 2H), 1.82-1.78 (m, 0.37H), 1.89-1.86 (m, 0.63H), 2.30-2.23 (m, 0.37H), 2.73-2.58 (m, 2.63H), 3.01 (d, $J = 13.5$ Hz, 0.37H), 3.34 (s, 1.9H), 3.38 (t, $J = 8.5$ Hz, 0.63H), 3.41 (s, 1.1H), 7.03-7.00 (m, 0.63H), 7.11-7.08 (m, 2H), 7.17-7.14 (m, 1H), 7.17-7.14 (m, 1H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz,

CDCl₃): δ 18.0, 23.5, 24.1, 24.5, 28.3, 29.1, 29.2, 29.4, 29.6, 35.2, 36.6, 38.2, 38.9, 40.3, 42.4, 42.6, 42.7, 42.8, 43.48, 43.9, 48.2, 49.2, 51.4, 51.7, 52.5, 52.7, 55.4, 122.1, 122.7, 124.2, 125.3, 126.3, 127.3, 128.2, 128.2, 132.6, 135.2, 143.1, 144.1, 176.7, 178.4; LRMS (EI, 70 eV) m/z (%): 311 (M^+ , 64), 283 (24), 188 (19), 120 (100); HRMS m/z (ESI) calcd for C₂₁H₃₀NO ($[M+H]^+$) 312.2322, found 312.2328.


3a,5-Dimethyl-1,3,3a,4',5,5',10,10a-octahydro-3'H,4H-spiro[benzo[b]cyclopenta[e]azepine-2,2'-furan]-4-one (3af), 35.3mg, 62% yield:



Colorless oil; ¹H NMR (500 MHz, CDCl₃): δ 0.91 (s, 3H), 1.56-1.52 (m, 2H), 1.90-1.83 (m, 3H), 1.97-1.93 (m, 2H), 2.46-2.41 (m, 1H), 2.65-2.59 (m, 2H), 3.18 (d, J = 14.5Hz, 1H), 3.42 (s, 3H), 3.79-3.76 (m, 2H), 7.13-7.09 (m, 2H), 7.16

(d, J = 7.0 Hz, 1H), 7.28-7.25 (m, 1H); ¹³C {¹H} NMR (125 MHz, CDCl₃): δ 25.6, 27.9, 34.5, 36.3, 38.4, 45.8, 49.2, 52.1, 55.8, 66.6, 88.5, 122.2, 125.5, 127.5, 128.4, 135.3, 143.8, 143.8; LRMS (EI, 70 eV) m/z (%): 285 (M^+ , 100), 174 (48), 161 (63), 120 (97); HRMS m/z (ESI) calcd for C₁₈H₂₄NO₂ ($[M+H]^+$) 286.1802, found 286.1809.


2,2,3a,5,10-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ag), 31.4mg, 58% yield; (dr = 2:1):



Yellow oil; ¹H NMR (500 MHz, CDCl₃): δ 0.75 (s, 1H), 0.82 (s, 2H), 0.97 (s, 1H), 1.05 (s, 2H), 1.10 (d, J = 2.5 Hz, 3H), 1.30 (t, J = 6.5 Hz, 3H), 1.49-1.39 (m, 2H), 1.73-1.69 (m, 0.33H), 1.88-1.84

(m, 0.67H), 1.97-1.93 (m, 0.33H), 2.39-2.33 (m, 0.67H), 2.64 (d, J = 14.0 Hz, 0.67H), 2.81-2.72 (m, 1H), 3.10 (d, J = 14.0 Hz, 0.33H), 3.33 (s, 2H), 3.41 (s, 1H), 7.12-7.05 (m, 2.33H), 7.21-7.16 (m, 1H), 7.28-7.25 (m, 0.67H); ¹³C {¹H} NMR (125 MHz, CDCl₃): δ 17.3, 18.0, 25.8, 28.1, 29.0, 30.3, 31.7, 31.8, 34.6, 36.0, 37.4, 38.1, 38.3, 41.5, 48.6, 48.9, 51.7, 52.1, 52.7, 53.0, 62.8, 122.0, 122.9, 122.9, 124.9, 125.5, 126.6, 127.0, 130.8, 139.2, 139.3, 142.1, 143.8, 176.5, 176.5; LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 69), 256 (100), 174 (10), 134 (57); HRMS m/z (ESI) calcd for C₁₈H₂₆NO ($[M+H]^+$) 272.2009, found 272.2001.

5,6a,8,8-Tetramethyl-5,6a,7,8,9,10,10a,11-octahydro-6*H*-dibenzo[*b,e*]azepin-6-one (3ah), 34.1mg, 63% yield; (dr = 2:1):







Colorless oil; ^1H NMR (500 MHz, CDCl_3): δ 0.75 (s, 1.1H), 0.82 (s, 1.9H), 0.97 (s, 1.1H), 1.05 (s, 1.9H), 1.10 (d, $J = 2.5$ Hz, 3H), 1.17-1.14 (m, 0.37H), 1.30 (t, $J = 6.5$ Hz, 3H), 1.49-1.39 (m, 1.63H), 1.73-1.69 (m, 0.37H), 1.88-1.84 (m, 0.63H), 1.97-1.91 (m, 0.37H), 2.39-2.33 (m, 0.63H), 2.65 (d, $J = 14.0$ Hz, 0.63H), 2.81-2.72 (m, 1H), 3.10 (d, $J = 13.5$ Hz, 0.37H), 3.34 (s, 1.9H), 3.41 (s, 1.1H), 7.12-7.05 (m, 2.37H), 7.21-7.16 (m, 1H), 7.28-7.25 (m, 0.63H); $^{13}\text{C}\{^1\text{H}\}$ NMR (125 MHz, CDCl_3): δ 17.3, 18.1, 25.8, 28.1, 29.0, 30.3, 31.7, 31.8, 34.6, 36.0, 37.4, 38.1, 38.3, 41.5, 48.6, 48.9, 51.7, 52.1, 52.6, 53.0, 62.8, 122.0, 122.9, 124.4, 124.9, 125.5, 126.6, 127.0, 130.8, 139.2, 139.3, 142.1, 143.8, 176.5, 178.2; LRMS (EI, 70 eV) m/z (%): 271 (M^+ , 42), 243 (39), 158 (100), 134 (97); HRMS m/z (ESI) calcd for $\text{C}_{18}\text{H}_{26}\text{NO}$ ($[\text{M}+\text{H}]^+$) 272.2009, found 272.2013.

(C) Spectra

2,2,3a,5-Tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-


4(1H)-one (3aa):








5-Cyclohexyl-2,2,3a-trimethyl-2,3,3a,5,10,10a-



hexahydrobenzo[b]cyclopenta[e]azepin-4(1*H*)-one (3ba)










5-Benzyl-2,2,3a-trimethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ca)








2,2,3a-Trimethyl-5-phenyl-2,3,3a,5,10,10a-

hexahydrobenzo[b]cyclopenta[c]azepin-4(1*H*)-one (3da)








2,2,3a-Trimethyl-5-tosyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ea)




2,2,3a,5,8-Pentamethyl-2,3,3a,5,10a-hexahydrobenzo[b]cyclopenta[e]azepin-



4(1*H*)-one (3ga)












8-Methoxy-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ha)







8-Fluoro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-
hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ia)







**8-Chloro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-
hexahydrobenzo[b]cyclopenta[e]azepin-4(1*H*)-one (3ja)**





8-Bromo-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-


hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ka)






2,2,3a,5-Tetramethyl-8-(trifluoromethyl)-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3la)







6-Chloro-2,2,3a,5-tetramethyl-2,3,3a,5,10,10a-

hexahydrobenzo[b]cyclopenta[e]azepin-4(1*H*)-one (3ma)







H-H NOSEY




H-C HMBC





H-C HSQC



H-C HSQC





2,2,3a,5,7-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1*H*)-one (3na)





2,2,3a,5,9-Pentamethyl-2,3,3a,5,10a-hexahydrobenzo[b]cyclopenta[e]azepin-

4(1*H*)-one (3na')







2,2,5-Trimethyl-3a-phenyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (30a)




H-H NOSEY




H-C HMBC



H-C HSQC




H-C HSQC




5,6a,8,8-Tetramethyl-1,2,3,5,6a,7,8,9,9a,10-decahydro-6H-



cyclopenta[e]indeno[5,6-b]azepin-6-one (3pa)




2,2-Diethyl-3a,5-dimethyl-2,3,3a,5,10,10a-



hexahydrobenzo[b]cyclopenta[e]azepin-4(1H)-one (3ab)








**3a,5-Dimethyl-1,3,3a,5,10,10a-hexahydro-4*H*-
spiro[benzo[b]cyclopenta[e]azepine-2,1'-cyclobutan]-4-one (3ac)**










3a,5-Dimethyl-1,3,3a,5,10,10a-hexahydro-4H-


spiro[benzo[b]cyclopenta[e]azepine-2,1'-cycloheptan]-4-one (3ae)






**3a,5-Dimethyl-1,3,3a,4',5,5',10,10a-octahydro-3'*H*,4*H*-
spiro[benzo[*b*]cyclopenta[*e*]azepine-2,2'-furan]-4-one (3af)**







H-H NOSEY




H-C HMBC






H-C HSQC




H-C HSQC





2,2,3a,5,10-Pentamethyl-2,3,3a,5,10,10a-hexahydrobenzo[b]cyclopenta[e]azepin-4(1*H*)-one (3ag)





5,6a,8,8-Tetramethyl-5,6a,7,8,9,10,10a,11-octahydro-6H-dibenzo[b,e]azepin-6-one (3ah)





(D) The X-ray single-crystal diffraction analysis of 3ca

(CCDC 1941546)

